Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when SGRY files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SGRY Surgery Partners, Inc. 8-K

Surgery Partners holds routine annual meeting, re-elects directors through 2029

Filed June 5, 2026 · Period ending June 5, 2026 · ~1 min read

3 key changes

Key Changes

  • low

    Shareholders re-elected three Class II directors (Devin O'Reilly, Brent Turner, and Laura L. Forese, M.D.) to serve until the 2029 annual meeting. All three were incumbents standing for re-election.

  • low

    Executive compensation approved on advisory basis with 111.6 million votes for versus 2.0 million against. This non-binding say-on-pay vote is a routine regulatory requirement.

  • low

    Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 119.8 million votes in favor, confirming the audit committee's selection.

Summary

Surgery Partners filed a routine 8-K disclosing results from its 2026 Annual Meeting of Stockholders held June 5, 2026. The meeting produced no surprises: shareholders re-elected the three incumbent Class II directors to three-year terms, approved executive compensation on an advisory basis by a wide margin, and ratified the company's choice of Ernst & Young as external auditor for the current fiscal year. For retail investors, this filing signals business as usual with no governance changes or shareholder dissent.

The strong vote tallies across all proposals suggest alignment between management and shareholders. Board continuity remains intact through 2029 for the re-elected directors. Watch for the company's next quarterly earnings report or operational updates for material developments affecting the business.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify